AU2004283710A1 - Inosine monophosphate dehydrogenase inhibitors as phosphonate derivatives - Google Patents

Inosine monophosphate dehydrogenase inhibitors as phosphonate derivatives Download PDF

Info

Publication number
AU2004283710A1
AU2004283710A1 AU2004283710A AU2004283710A AU2004283710A1 AU 2004283710 A1 AU2004283710 A1 AU 2004283710A1 AU 2004283710 A AU2004283710 A AU 2004283710A AU 2004283710 A AU2004283710 A AU 2004283710A AU 2004283710 A1 AU2004283710 A1 AU 2004283710A1
Authority
AU
Australia
Prior art keywords
compound
formula
pct
ethyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004283710A
Other languages
English (en)
Inventor
Aesop Cho
Lee S. Chong
Maria Fardis
Thorsten A. Kirschberg
William J. Watkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2004/013143 external-priority patent/WO2004096236A2/en
Priority claimed from PCT/US2004/013064 external-priority patent/WO2004096287A2/en
Priority claimed from PCT/US2004/013121 external-priority patent/WO2004096235A2/en
Priority claimed from PCT/US2004/013063 external-priority patent/WO2004096286A2/en
Priority claimed from PCT/US2004/013198 external-priority patent/WO2004100960A2/en
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AU2004283710A1 publication Critical patent/AU2004283710A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2004283710A 2003-10-24 2004-10-25 Inosine monophosphate dehydrogenase inhibitors as phosphonate derivatives Abandoned AU2004283710A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US51425803P 2003-10-24 2003-10-24
US60/514,258 2003-10-24
AUPCT/US2004/013063 2004-04-26
AUPCT/US2004/013143 2004-04-26
AUPCT/US2004/013121 2004-04-26
PCT/US2004/013143 WO2004096236A2 (en) 2003-04-25 2004-04-26 Immunomodulator phosphonate conjugates
PCT/US2004/013064 WO2004096287A2 (en) 2003-04-25 2004-04-26 Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
PCT/US2004/013121 WO2004096235A2 (en) 2003-04-25 2004-04-26 Anti-cancer phosphonate analogs
PCT/US2004/013063 WO2004096286A2 (en) 2003-04-25 2004-04-26 Antiviral phosphonate analogs
AUPCT/US2004/013198 2004-04-26
AUPCT/US2004/013064 2004-04-26
PCT/US2004/013198 WO2004100960A2 (en) 2003-04-25 2004-04-26 Anti-inflammatory phosphonate compounds
PCT/US2004/035136 WO2005039552A2 (en) 2003-10-24 2004-10-25 Inosine monophosphate dehydrogenase inhibitors as phosphonate derivatives

Publications (1)

Publication Number Publication Date
AU2004283710A1 true AU2004283710A1 (en) 2005-05-06

Family

ID=38344791

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004283710A Abandoned AU2004283710A1 (en) 2003-10-24 2004-10-25 Inosine monophosphate dehydrogenase inhibitors as phosphonate derivatives

Country Status (7)

Country Link
US (1) US20070027116A1 (de)
EP (1) EP1680129A2 (de)
JP (1) JP2007520452A (de)
CN (1) CN101410120A (de)
AU (1) AU2004283710A1 (de)
CA (1) CA2542967A1 (de)
WO (1) WO2005039552A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096286A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Antiviral phosphonate analogs
MXPA06005659A (es) 2004-04-26 2007-04-10 Teva Gyogyszergyar Zartkoruen Proceso para preparacion de acido micofenolico y derivados de ester del mismo.
WO2006110157A2 (en) 2004-07-27 2006-10-19 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
EP1906971A2 (de) * 2005-07-27 2008-04-09 Gilead Sciences, Inc. Antivirale verbindungen
DE102005057924A1 (de) * 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
PL2307435T3 (pl) 2008-07-08 2012-11-30 Gilead Sciences Inc Sole związków inhibitorów HIV
CA2744987C (en) 2008-12-02 2018-01-16 Chiralgen, Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
EA201190178A1 (ru) * 2009-03-20 2012-06-29 Алиос Биофарма, Инк. Замещённые нуклеозидные и нуклеотидные аналоги
WO2010120386A1 (en) 2009-04-17 2010-10-21 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
WO2010120388A1 (en) 2009-04-17 2010-10-21 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
CA2767253A1 (en) 2009-07-06 2011-01-13 Ontorii, Inc. Novel nucleic acid prodrugs and methods of use thereof
JP6012605B2 (ja) 2010-09-22 2016-10-25 アリオス バイオファーマ インク． 置換されたヌクレオチドアナログ
EP2620428B1 (de) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetrische hilfsgruppe
EP3248982A1 (de) 2011-07-19 2017-11-29 Wave Life Sciences Ltd. Thiosulfonate reagente zur synthese von funktionalisierten nukleinsäuren
US8980865B2 (en) 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
EP2827876A4 (de) 2012-03-22 2015-10-28 Alios Biopharma Inc Pharmazeutische kombinationen mit einem thionucleotidanalog
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
RU2016133035A (ru) 2014-01-16 2018-02-21 Уэйв Лайф Сайенсес Лтд. Хиральный дизайн
CN107427529A (zh) 2014-12-26 2017-12-01 埃莫里大学 N4‑羟基胞苷和衍生物及与其相关的抗病毒用途
CN106565769B (zh) * 2016-11-12 2018-12-04 北京汇康博源医药科技有限公司 恩替卡韦中间体的合成工艺
PL3661937T3 (pl) 2017-08-01 2021-12-20 Gilead Sciences, Inc. Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
CN110726801A (zh) * 2019-10-31 2020-01-24 山东泰星新材料股份有限公司 一种监测烷基次膦酸反应状态的方法
IT202100005777A1 (it) 2021-03-11 2022-09-11 Hippocrates Res S R L Composizione per l’uso nel trattamento dell’occhio secco

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631370A (en) * 1988-01-20 1997-05-20 Regents Of The University Of Minnesota Optically-active isomers of dideoxycarbocyclic nucleosides
US5177064A (en) * 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
US5610294A (en) * 1991-10-11 1997-03-11 The Du Pont Merck Pharmaceutical Company Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5654286A (en) * 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
EP0708760A1 (de) * 1993-07-14 1996-05-01 Novartis AG Cyclische hydrazin-verbindungen
US5446137B1 (en) * 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5493030A (en) * 1994-02-18 1996-02-20 Syntex (U.S.A.) Inc. 5-substituted derivatives of mycophenolic acid
US5854227A (en) * 1994-03-04 1998-12-29 Hartmann; John F. Therapeutic derivatives of diphosphonates
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5750493A (en) * 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5874577A (en) * 1996-04-03 1999-02-23 Medichem Research, Inc. Method for the preparing 9-12-(Diethoxyphosphonomethoxy)ethyl!adenine and analogues thereof
JP4033494B2 (ja) * 1996-07-26 2008-01-16 ギリヤド サイエンシーズ， インコーポレイテッド ヌクレオチドアナログ
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
US6174888B1 (en) * 1998-05-28 2001-01-16 Novartis Ag 2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydropyrrolo[3,2-D]pyrimidin-4-ones
TWI260322B (en) * 1999-02-12 2006-08-21 Vertex Pharma Inhibitors of aspartyl protease
US6258831B1 (en) * 1999-03-31 2001-07-10 The Procter & Gamble Company Viral treatment
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
ATE248835T1 (de) * 1999-06-25 2003-09-15 Vertex Pharma Prodrugs von impdh-inhibierenden carbamaten
CN1426418A (zh) * 2000-02-29 2003-06-25 三菱制药株式会社 膦酸酯核苷酸化合物
KR100749160B1 (ko) * 2000-07-21 2007-08-14 길리애드 사이언시즈, 인코포레이티드 포스포네이트 뉴클레오티드 유사체의 전구 약물의 제조방법
KR20020097384A (ko) * 2001-06-20 2002-12-31 미쯔비시 도꾜 세이야꾸 가부시끼가이샤 기존의 약제에 내성변이를 가지는 바이러스에 유효한 약제
PL211979B1 (pl) * 2002-04-26 2012-07-31 Gilead Sciences Pochodne fosfonianowe, ich zastosowanie w leczeniu zakażenia wirusem HIV i chorób wpływających na białe krwinki, oraz kompozycje farmaceutyczne zawierające te związki
EP2298783B1 (de) * 2003-02-19 2017-12-06 Yale University Antivirale Nukleosid-Analoga und Verfahren zur Behandlung von Virusinfektionen, insbesondere HIV-Infektionen

Also Published As

Publication number Publication date
US20070027116A1 (en) 2007-02-01
WO2005039552A2 (en) 2005-05-06
WO2005039552A3 (en) 2005-06-09
CN101410120A (zh) 2009-04-15
CA2542967A1 (en) 2005-05-06
EP1680129A2 (de) 2006-07-19
JP2007520452A (ja) 2007-07-26

Similar Documents

Publication Publication Date Title
AU2005267800B2 (en) Nucleoside phosphonate conjugates as anti HIV agents
CA2523083C (en) Antiviral phosphonate analogs
US7642339B2 (en) Antiviral compounds
DE60315023T2 (de) Anreicherung in der zelle an phosphonat analoga von hiv protease inhibitor verbindungen und die verbindungen selbst
US20070027116A1 (en) Therapeutic phosphonate derivatives
AU2006267066A1 (en) Antiviral compounds
AU2006270264A1 (en) Antiviral compounds
AU2004308974A1 (en) Kinase inhibitor phosphonate conjugates
US20060035866A1 (en) Phosphonate compounds having immuno-modulatory activity
AU2006272521A1 (en) Antiviral phosphonate conjugates for inhibition of HIV
AU2004260789B2 (en) Nucleobase phosphonate analogs for antiviral treatment
US7427636B2 (en) Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
AU2005299284A1 (en) Phosphonate derivatives of mycophenolic acid
WO2005044308A1 (en) Phosphonate analogs of antimetabolites
EP1620110A2 (de) Immunomodulatorische phosphonat konjugate
AU2011218664B2 (en) Antiviral compounds
AU2005299504A1 (en) Phosphonate substituted kinase inhibitors

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application